Clinical Trial Update: Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and relatlimab for newly diagnosed glioblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Duke University | Conditions: Newly Diagnosed Glioblastoma | Phase 2 | Status: RECRUITING